Real-World Eligibility for Adjuvant CDK4/6 Inhibitor Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

Authors
Category Primary study
Registry of TrialsClinical Trials Registry - India
Year 2026
This article has no abstract
Epistemonikos ID: bb515b1879c4ce6f6a4433e9c25087994d11873c
First added on: Oct 10, 2026